N4 Pharma PLC (N4P)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

0.45p

Buy

0.50p

arrow-up0.00p (+0.00%)

N4 Pharma PLC is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. Its vaccines include Nuvac and Nuvec.
Prices updated at 14 May 2025, 13:42 BST
| Prices minimum 15 mins delay
|
Prices in GBX
FTSE All-Share
arrow-down-0.14%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Income statement

Year
chevron-l-regular
chevron-r-regular
20162017201820192020202120222023
1m------1,953
221,000-------
-28,000-616,527-1m-947,340-2m-2m-1m-1m
-2.42-------68,377.83
-22,000-2m-1m-876,373-1m-2m-1m-1m
-22,000-2m-1m-947,340-2m-2m-1m-1m
Sales, General and administrative249,000316,632643,745730,392664,011663,865615,735717,980
Interest expenses-5,2999811,385----
Provision for income taxes--89,874-205,534-72,352-261,541-298,267-163,998-147,816
Operating expenses249,000616,5271m947,3402m2m1m1m
Income before taxes-22,000-2m-1m-948,725-2m-2m-1m-1m
Net income available to common shareholders-22,000-2m-1m-876,373-1m-2m-1m-1m
-0.0008-0.02836-0.0132-0.0087-0.0096-0.0085-0.0055-0.0052
Net interest income6,000-5,299-981-1,385-1,1506771-
Advertising and promotion--------
Net investment income, net-----813---89,175
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)-0.0008-0.02836-0.0132-0.0087-0.0096-0.0085-0.0055-0.0052
Free cash flow per share-0.0045-0.0171-0.01-0.0145-0.0057-0.0112-0.0053-0.0059
Book value/share0.01690.01930.01670.01310.0130.01490.00590.0054
Debt equity ratio--------

Balance sheet

Year
chevron-l-regular
chevron-r-regular
20162017201820192020202120222023
Current assets601,0001m1m1m4m2m2m1m
Current liabilities77,000179,218190,12377,683169,082212,73077,88981,726
Total capital1m1m879,944987,3384m2m2m1m
Total debt--------
Total equity1m1m879,944987,3384m2m2m1m
Total non current liabilities--------
Loans--------
Total assets1m1m1m1m4m2m2m1m
Total liabilities--------
Cash and cash equivalents172,0001m793,141965,7524m2m2m1m
Common stock45m77m91m101m181m181m234m269m

Cash flow

Year
chevron-l-regular
chevron-r-regular
20162017201820192020202120222023
Cash at beginning of period587,00019,7511m793,141965,7524m2m2m
Cash dividends paid--------
-376,000-950,800-1m-806,004-1m-2m-828,263-1m
Investments (gains) losses-39,000402,99027,693----781
172,0001m793,141965,7524m2m2m1m
Net income--------
-376,000-950,800-1m-806,004-1m-2m-828,263-1m
--------
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.